Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. („Janssen“) for the transition of a project into further drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-important-milestone-in-targetad-collaboration-with-janssen-in-alzheimers-disease-5335
Evotec and UCB sign multi-year sample management agreement
Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB’s global sample management requirements. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-sample-management-agreement-5333
Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials
Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-spero-therapeutics-extend-collaboration-to-develop-novel-antibacterials-10
Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare
Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-important-pre-clinical-milestones-as-part-of-its-multi-target-alliance-with-bayer-healthcare-11
Huntington’s disease and the hope for a treatment
Hamburg, Germany – 20 November 2015: Evotec announced that Charles Sabine, former Emmy-awarded NBC News journalist and a high-profile spokesman for the global Huntington’s disease community, gave a lecture on “Why … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/huntingtons-disease-and-the-hope-for-a-treatment-5324
Evotec AG reports results of the first nine months of 2015
– STRONG GROWTH IN REVENUES AND PROFITS – THREE MAJOR EVT INNOVATE DEALS CONCLUDED – REVENUE GUIDANCE RAISED ON 15 SEPTEMBER 2015 Hamburg, Germany – 10 November 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-the-first-nine-months-of-2015-5321
Evotec and Beyond Batten Disease Foundation collaborate to advance emerging therapies to fight juvenile Batten Disease
Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-beyond-batten-disease-foundation-collaborate-to-advance-emerging-therapies-to-fight-juvenile-batten-disease-5317
Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center
Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-multi-year-contract-to-manage-national-cancer-institute-chemical-biology-consortium-screening-libraries-center-5315
Evotec AG increases its revenue guidance for 2015
Evotec AG today announced that it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-increases-its-revenue-guidance-for-2015-12
Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis
Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-licence-and-collaboration-agreement-with-pfizer-inc-in-tissue-fibrosis-5309